KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income - MinorityNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Teva Pharmaceutical Industries (TEVA) EPS (Basic) (2016 - 2025)

Teva Pharmaceutical Industries' EPS (Basic) history spans 10 years, with the latest figure at $0.42 for Q4 2025.

  • For the quarter ending Q4 2025, EPS (Basic) rose 321.05% year-over-year to $0.42, compared with a TTM value of $1.24 through Dec 2025, up 185.52%, and an annual FY2025 reading of $1.23, up 184.83% over the prior year.
  • EPS (Basic) for Q4 2025 was $0.42 at Teva Pharmaceutical Industries, up from $0.38 in the prior quarter.
  • The five-year high for EPS (Basic) was $0.42 in Q4 2025, with the low at -$1.17 in Q4 2022.
  • Average EPS (Basic) over 5 years is -$0.13, with a median of -$0.04 recorded in 2024.
  • Year-over-year, EPS (Basic) crashed 1328.57% in 2022 and then soared 321.05% in 2025.
  • Tracing TEVA's EPS (Basic) over 5 years: stood at -$0.14 in 2021, then crashed by 735.71% to -$1.17 in 2022, then soared by 135.04% to $0.41 in 2023, then plummeted by 146.34% to -$0.19 in 2024, then soared by 321.05% to $0.42 in 2025.
  • Per Business Quant, the three most recent readings for TEVA's EPS (Basic) are $0.42 (Q4 2025), $0.38 (Q3 2025), and $0.25 (Q2 2025).